Àvida Biotech

Startup

Àvida Biotech is an early-stage virtual biotech based in Barcelona. We are developing vaccines and therapies for diseases caused by enveloped viruses. We pursue a business model that revolves around four Sustainable Development Goals, particularly SDG#10: reducing inequalitites in access to life-saving drugs.

Our broad-spectrum antiviral is a technology platform that can generate a pipeline of products for human and animal health. It works via a mechanism of action that inactivates the virus while keeping it immunogenic. Our technology can be used as a scaffold to develop live attenuated virus vaccines as well as other products, including non-pharmaceutical products such as functional foods and devices for the prevention of mosquito-borne infections.

Our competitive advantage lies in the fact that our products will be thermostable and can be administered orally, which will significantly simplify logistics and reduce the costs of immunization programs.

We have validated our product in several cell-based models, including Dengue, Zika, Chikungunya, HIV, influenza and Covid-19. We have also seen oral immunization in a mouse model of Dengue.